Danimer Scientific (DNMR) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 14, 2023
Document Information [Line Items]
Entity Registrant Name	DANIMER SCIENTIFIC, INC.
Entity Central Index Key	0001779020
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Document Quarterly Report	true
Document Transition Report	false
Securities Act File Number	001-39280
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-1924518
Entity Address, Address Line One	140 Industrial Boulevard
Entity Address, City or Town	Bainbridge
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	39817
City Area Code	229
Local Phone Number	243-7075
Title of 12(b) Security	Class A Common stock, $0.0001 par value per share
Trading Symbol	DNMR
Security Exchange Name	NYSE
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		102,035,267

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 77,393	$ 62,792
Accounts receivable, net	12,422	17,989
Other receivables, net	715	1,635
Inventories, net	26,685	32,743
Prepaid expenses and other current assets	4,754	5,225
Contract assets, net	5,103	4,687
Total current assets	127,072	125,071
Property, plant and equipment, net	449,824	453,949
Intangible assets, net	78,660	80,941
Right-of-use assets	19,157	19,028
Leverage loans receivable	31,446	31,446
Restricted cash	14,461	1,609
Other assets	346	226
Total assets	720,966	712,270
Current liabilities
Accounts payable	3,909	14,977
Accrued liabilities	5,899	5,001
Deferred Revenue	438	0
Current portion of lease liability	3,337	3,337
Current portion of long-term debt, net	1,184	1,972
Total current liabilities	14,767	25,287
Private warrants liability	113	212
Long-term lease liability, net	21,965	22,114
Long-term debt, net	378,687	286,398
Deferred income taxes	0	200
Other long-term liabilities	1,153	447
Total liabilities	416,685	334,658
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized: 102,035,267 and 101,804,454 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	10	10
Additional paid-in capital	718,958	676,250
Accumulated deficit	(414,687)	(298,648)
Total stockholders’ equity	304,281	377,612
Total liabilities and stockholders’ equity	$ 720,966	$ 712,270

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.0001
Preferred stock, shares authorized	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	102,035,267	101,804,454
Common Stock, Shares, Outstanding	102,035,267	101,804,454

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 10,948	$ 10,448	$ 35,739	$ 37,894
Costs and expenses:
Cost of revenue	18,685	14,503	56,327	45,606
Selling, general and administrative	16,555	19,413	52,098	62,042
Research and development	6,883	7,947	21,667	24,469
Loss on sale of assets	64	0	234	1
Impairment of long-lived assets	0	63,491	0	63,491
Total costs and expenses	42,187	105,354	130,326	195,609
Loss from operations	(31,239)	(94,906)	(94,587)	(157,715)
Nonoperating income (expense):
Gain on remeasurement of private warrants	132	1,607	99	8,614
Interest, net	(8,584)	(553)	(21,132)	(2,197)
Loss on loan extinguishment	0	(1,500)	(102)	(1,500)
Other, net	0	240	0	324
Total nonoperating income (expenses)	(8,452)	(206)	(21,135)	5,241
Loss before income taxes	(39,691)	(95,112)	(115,722)	(152,474)
Income taxes	(468)	236	(317)	767
Net loss	$ (40,159)	$ (94,876)	$ (116,039)	$ (151,707)
Net loss per share:
Basic net loss per share	$ (0.39)	$ (0.94)	$ (1.14)	$ (1.5)
Diluted net loss per share	$ (0.39)	$ (0.94)	$ (1.14)	$ (1.5)
Basic - Weighted Average Number Of Shares Outstanding	102,025,684	101,199,195	101,953,827	100,993,068
Diluted - Weighted Average Number Of Shares Outstanding	102,025,684	101,199,195	101,953,827	100,993,068
Products
Revenue:
Total revenue	$ 10,454	$ 9,099	$ 33,724	$ 33,890
Services
Revenue:
Total revenue	$ 494	$ 1,349	$ 2,015	$ 4,004

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Total stockholders’ equity		$ 10	$ 619,145	$ (118,890)
Balance, beginning of period at Dec. 31, 2021		10	619,145	(118,890)
Costs related to warrants			(55)
Stock-based compensation expense			42,398
Warrants issued with Senior Secured Term Loan			0
Stock issued under stock compensation plan			741
Issuance of common stock, net of issuance costs		0	79
Shares retained for employee taxes			0
Net loss	$ (151,707)			(151,707)
Balance, end of period at Sep. 30, 2022	391,721	10	662,308	(270,597)
Total stockholders’ equity		10	647,566	(175,721)
Balance, beginning of period at Jun. 30, 2022		10	647,566	(175,721)
Costs related to warrants			0
Stock-based compensation expense			14,415
Warrants issued with Senior Secured Term Loan			0
Stock issued under stock compensation plan			248
Issuance of common stock, net of issuance costs		0	79
Shares retained for employee taxes			0
Net loss	(94,876)			(94,876)
Balance, end of period at Sep. 30, 2022	391,721	10	662,308	(270,597)
Total stockholders’ equity	391,721	10	662,308	(270,597)
Total stockholders’ equity	377,612	10	676,250	(298,648)
Balance, beginning of period at Dec. 31, 2022	377,612	10	676,250	(298,648)
Costs related to warrants			0
Stock-based compensation expense			42,227
Warrants issued with Senior Secured Term Loan			510
Stock issued under stock compensation plan			282
Issuance of common stock, net of issuance costs		0	(250)
Shares retained for employee taxes			61
Net loss	(116,039)			(116,039)
Balance, end of period at Sep. 30, 2023	304,281	10	718,958	(414,687)
Total stockholders’ equity		10	704,802	(374,528)
Balance, beginning of period at Jun. 30, 2023		10	704,802	(374,528)
Costs related to warrants			0
Stock-based compensation expense			14,253
Warrants issued with Senior Secured Term Loan			0
Stock issued under stock compensation plan			0
Issuance of common stock, net of issuance costs		0	(250)
Shares retained for employee taxes			0
Net loss	(40,159)			(40,159)
Balance, end of period at Sep. 30, 2023	304,281	10	718,958	(414,687)
Total stockholders’ equity	$ 304,281	$ 10	$ 718,958	$ (414,687)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (116,039)	$ (151,707)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	42,227	42,398
Depreciation and amortization	22,005	13,172
Amortization of debt issuance costs	6,209	1,601
Accounts receivable reserves	(1,462)	1,205
Inventory reserves	540	609
Amortization of right-of-use assets and lease liability	(278)	(270)
Loss on disposal of assets	234	0
Deferred income taxes	(199)	(767)
Loss on extinguishment of debt	102	1,500
Gain on remeasurement of private warrants	(99)	(8,614)
Contract asset reserve	0	1,215
Impairment of long-lived assets	0	63,491
Other	941	43
Changes in operating assets and liabilities
Accounts receivable	7,029	(1,747)
Other receivables	555	2,724
Inventories, net	5,475	(14,271)
Prepaid expenses and other current assets	1,816	1,749
Contract assets	(1,244)	(2,019)
Other assets	(119)	(5)
Accounts payable	(2,061)	(4,642)
Accrued liabilities	1,893	(5,037)
Other long-term liabilities	706	3
Unearned revenue and contract liabilities	438	1,786
Net cash used in operating activities	(31,331)	(57,582)
Cash flows from investing activities:
Purchases of property, plant and equipment and intangible assets	(25,722)	(133,632)
Proceeds from sales of property, plant and equipment	18	55
Investment in leverage loan receivable related to NMTC financing	0	(18,037)
Acquisition of Novomer, net of cash acquired	0	(14)
Net cash used in investing activities	(25,704)	(151,628)
Cash flows from financing activities:
Proceeds from long-term debt	130,000	24,700
Cash paid for debt issuance costs	(33,296)	(1,547)
Principal payments on long-term debt	(12,437)	(886)
Proceeds from employee stock purchase plan	282	526
Employee taxes related to stock-based compensation	(61)	0
Proceeds from exercise of stock options	0	215
Proceeds from issuance of common stock, net of issuance costs	0	79
Cost related to warrants	0	(55)
Net cash provided by financing activities	84,488	23,032
Net increase (decrease) in cash and cash equivalents and restricted cash	27,453	(186,178)
Cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash-beginning of period	64,401	286,968
Cash and cash equivalents and restricted cash-end of period	91,854	100,790
Supplemental cash flow information:
Cash paid for interest, net of interest capitalized	16,349	0
Cash paid for operating leases	$ 2,787	$ 2,657

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Note 1. Basis of Presentation Description of Business Danimer Scientific, Inc., together with its subsidiaries (“Company”, “Danimer”, “we”, “us”, or “our”), is a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Our common stock is listed on the New York Stock Exchange under the symbol “DNMR”. The Company (formerly Live Oak Acquisition Corp. (“Live Oak”)), was originally incorporated in the State of Delaware on May 24, 2019 as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. Live Oak completed its initial public offering in May 2020. On December 29, 2020 (“Closing Date”), Live Oak consummated a business combination (“Business Combination”) with Meredian Holdings Group, Inc. (“MHG” or “Legacy Danimer”), with Legacy Danimer surviving the merger as a wholly owned subsidiary of Live Oak. The Business Combination was accounted for as a reverse recapitalization, meaning that Legacy Danimer was treated as the accounting acquirer and Live Oak was treated as the accounting acquiree. Effectively, the Business Combination was treated as the equivalent of Legacy Danimer issuing stock for the net assets of Live Oak, accompanied by a recapitalization. In connection with the Business Combination, Live Oak changed its name to Danimer Scientific, Inc. On August 11, 2021, we closed the acquisition of Novomer, Inc. (integrated into our business as “Danimer Catalytic Technologies”). Financial Statements The accompanying condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and consolidate all assets and liabilities of the Company and its wholly owned subsidiaries. GAAP requires us to make certain estimates and assumptions in recording assets, liabilities, sales and expenses as well as in the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. All intercompany transactions and balances have been eliminated. Certain reclassifications have been made to previously reported amounts to conform to the current presentation. In preparing these condensed consolidated financial statements, we have considered and, where appropriate, included the effects of the COVID-19 pandemic on our operations. The pandemic continues to provide significant challenges to the U.S. and global economies. We do no t have any material items of other comprehensive income (loss); accordingly, there is no difference between net loss and comprehensive (loss) income and we have not presented a separate Statement of Comprehensive Income (Loss) that would otherwise be required. Recently Issued Accounting Pronouncements There have been no new accounting pronouncements not yet effective that we believe will have a significant effect, or potential significant effect, on our condensed consolidated financial statements.

Fair Value Considerations

Fair Value Considerations	9 Months Ended
	Sep. 30, 2023
Fair Value Considerations [Abstract]
Fair Value Considerations	Note 2. Fair Value Considerations GAAP defines “fair value” as the price we would receive to sell an asset in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer. GAAP also sets forth a framework for measuring fair value utilizing a three-tier hierarchy based on the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of the fair value hierarchy are as follows: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities; Level 2 - Observable inputs other than quoted prices in active markets, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and Level 3 - Unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. Level 1 The carrying amounts of our cash and cash equivalents and restricted cash were measured using quoted market prices in active markets and represent Level 1 investments. Our other financial instruments such as accounts receivable, accounts payable and accrued liabilities, approximate their fair values due to their short maturities. The September 30, 2023 fair value of our Senior Secured Term Loan, based on an analysis of market activity since loan inception, was approximately $ 87.3 million. The September 30, 2023 fair value of our Convertible Notes (See Note 10), based on trades made around that date, was approximat ely $ 78.3 million. We value our restricted stock and restricted stock units without market-based vesting provisions on the respective grant dates, at the closing price of a share of our common stock on the grant dates. We re-value our restricted stock units that include a cash settlement feature each month at the closing price of a share of our common stock on the last trading day of the month, or $ 2.07 at September 30, 2023. Level 2 We valued our restricted stock awards that contain a market-based vesting provision on the grant date using a Monte Carlo simulation, which takes into account a large number of potential stock price scenarios over time and incorporates varied assumptions about volatility and exercise behavior for those various scenarios. These assumptions are based on market data but cannot be directly observed. A fair value is estimated for each potential outcome and these fair values are averaged to arrive at an overall fair value. Level 3 We value our stock options, including our ESPP (See Note 13), and Private Warrants (See Note 9) using the Black-Scholes option pricing model on the respective grant dates. We re-value the Private Warrants and any stock options with a cash-settlement feature each period end. Since our stock price history as a publicly traded company is shorter in duration than the expected lives of our options (other than ESPP), we use a peer group to assess volatility. We have not paid and do not currently anticipate paying a cash dividend on our common stock, so we have set the expected annual dividend yield to zero for all calculations. We used risk-free rates equal to the U.S. Treasury yield curves in effect as of each valuation date for durations equal to the expected lives of each instrument. We use the simplified method under Staff Accounting Bulletin Topic 14, defined as the mid-point between the vesting period and the contractual term for each option, to determine the expected lives of stock options, and we use the remaining contractual life of the warrants as their expected life. The following table sets forth the ranges of calculated fair values and the associated ranges of values we used for remeasurement in our Black-Scholes calculations for stock options, other than ESPP. Three Months Ended September 30, 2023 2022 Share prices of our common stock $ 2.07 $ 2.95 - $ 4.81 Expected volatilities 51.76 % - 55.88 % 47.55 % - 49.38 % Risk-free rates of return 4.50 % - 4.61 % 2.93 % - 4.00 % Expected option terms (years) 3.82 - 5.42 4.81 - 6.00 Calculated option values $ 0.04 -$ 0.95 $ 0.12 - $ 2.25 The following table sets forth the fair values we calculated and the inputs we used in our Black-Scholes models for Private Warrants. September 30, December 31, 2023 2022 Share prices of our common stock $ 2.07 $ 1.79 Expected volatilities 53.33 % 55.83 % Risk-free rates of return 4.92 % 4.13 % Expected warrant term (years) 2.25 3.00 Calculated Private Warrant values $ 0.03 $ 0.05

Inventories

Inventories	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories, Net	Note 3. Inventories, net Inventories, net consisted of the following: September 30, December 31, (in thousands) 2023 2022 Raw materials $ 10,936 $ 19,964 Work in process 762 1,524 Finished goods and related items 14,987 11,255 Total inventories, net $ 26,685 $ 32,743 At September 30, 2023 and December 31, 2022, finished goods and related items included $ 8.8 million and $ 4.9 million, respectively, of finished neat PHA. Inventory at September 30, 2023 is stated net of reserves of $ 0.5 million related to interim assessments to reduce the carrying value of inventory to its fair value.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Note 4. Property, Plant and Equipment, net Property, plant and equipment, net, consisted of the following: September 30, December 31, (in thousands) Estimated Useful Life (Years) 2023 2022 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful life or lease term 110,387 109,805 Buildings 15 - 40 2,191 2,156 Machinery and equipment 5 - 20 183,797 180,846 Motor vehicles 7 - 10 921 921 Furniture and fixtures 7 - 10 474 473 Office equipment 3 - 10 6,871 5,976 Construction in progress N/A 208,367 198,545 513,100 498,814 Accumulated depreciation and amortization ( 63,276 ) ( 44,865 ) Property, plant and equipment, net $ 449,824 $ 453,949 We reported depreciation and amortization expense (including amortization of intangible assets) as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 5,086 $ 2,571 $ 15,233 $ 7,087 Research and development 1,865 1,839 5,903 5,587 Selling, general and administrative 302 175 869 498 Total depreciation and amortization expense $ 7,253 $ 4,585 $ 22,005 $ 13,172 Construction in progress consists primarily of the early phases of construction of our PHA plant in Bainbridge, Georgia (“Greenfield Facility”) and construction of a Rinnovo pilot plant in Rochester, New York as noted in the table below. (in thousands) September 30, December 31, Georgia $ 199,940 $ 191,576 New York 6,753 4,959 Kentucky 1,674 2,010 $ 208,367 $ 198,545 We do not have expected in-service dates for our Greenfield Facility, since we have paused major construction. We expect to place our Rinnovo pilot plant in Rochester, New York in service in 2023. We will need to obtain additional financing to complete our Greenfield Facility, which has an engineering cost estimate range from $ 515 million to $ 665 million, and if we do not obtain financing, our investment could be impaired. Property, plant and equipment includes gross capitalized interest of $ 14.9 million and $ 14.6 million as of September 30, 2023 and December 31, 2022, respectively. For the three months ended September 30, 2023 and 2022, interest costs of less than $ 0.1 million and $ 2.0 million, respectively, were capitalized to property, plant and equipment. For the nine months ended September 30, 2023 and 2022, interest costs of $ 0.3 million and $ 3.6 million, respectively, were capitalized to property, plant and equipment.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 5. Intangible Assets Our recognized intangible assets consist of patents and the unpatented technological know-how of Danimer Catalytic Technologies as well as patents arising from legacy Danimer, which were initially recorded at cost. The values of Danimer Catalytic Technologies’ patents and unpatented know-how are inseparable and represent their acquisition-date fair value, less subsequent amortization. We capitalize patent defense and application costs and amortize these costs on a straight-line basis over their estimated useful lives, which range from 13 to 20 years. Our intangible portfolio has an estimated weighted average useful life of 17.8 years. Intangible assets, net, consisted of the following: September 30, December 31, (in thousands) 2023 2022 Intangible assets, gross $ 95,565 $ 94,291 Less capitalized patent costs not yet subject to amortization ( 2,682 ) ( 1,604 ) Intangible assets subject to amortization, gross 92,883 92,687 Accumulated amortization, beginning balance ( 13,350 ) ( 8,585 ) Amortization in the quarter ended: March 31 ( 1,203 ) ( 1,181 ) June 30 ( 1,205 ) ( 1,186 ) September 30 ( 1,147 ) ( 1,185 ) December 31 - ( 1,213 ) Accumulated amortization, ending balance ( 16,905 ) ( 13,350 ) Intangible assets subject to amortization, net 75,978 79,337 Total intangible assets, net $ 78,660 $ 80,941

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2023
Accounts Payable and Accrued Liabilities [Abstract]
Accrued Liabilities	Note 6. Accrued Liabilities The components of accrued liabilities were as follows: September 30, December 31, (in thousands) 2023 2022 Accrued interest $ 2,390 $ 134 Compensation and related expenses 1,352 1,305 Accrued taxes 1,002 669 Accrued utilities 304 415 Accrued legal, professional and consulting fees 286 443 Construction in progress accruals 94 1,089 Purchase accrual 31 401 Other 440 545 Total accrued liabilities $ 5,899 $ 5,001

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 7. Income Taxes We reported income tax expense for the three months and nine months ended September 30, 2023 of $ 0.5 million and $ 0.3 million, respectively, which resulted in effective income tax rates of negative 1.18 % and negative 0.27 % , respectively. We reported income tax benefits for the three and nine months ended September 30, 2022 of $ 0.2 million and $ 0.8 million, respectively, which resulted in effective income tax rates of 0.25 % and 0.50 % , respectively. Our effective tax rates differed from the federal statutory rate of 21 % due to our valuation allowances against substantially all of our net deferred tax assets. In assessing the realizability of deferred income tax assets, we consider whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods at which time those temporary differences become deductible. In making valuation allowance determinations, we consider all available evidence, positive and negative, affecting specific deferred income tax assets, including the scheduled reversal of deferred income tax liabilities, projected future taxable income, the length of carry-back and carry-forward periods, and tax planning strategies in making this assessment. At September 30, 2023, we maintained a partial valuation allowance against our net deferred income tax assets due to the uncertainty surrounding realization of such assets.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Disclosure Text Block [Abstract]
Leases	Note 8. Leases The following table sets forth the allocation of our operating lease costs. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 673 $ 626 $ 1,927 $ 1,880 Research and development 457 113 668 423 Selling, general and administrative ( 179 ) 136 101 333 Total operating lease cost $ 951 $ 875 $ 2,696 $ 2,636 We currently lease our facility in Winchester, Kentucky and certain facilities in Bainbridge, Georgia under an operating lease. As of December 31, 2022, the lease had a remaining term of 16 years. During the nine months ended September 30, 2023, we concluded that it is reasonably certain that we will exercise our four, five-year extension options under the lease, resulting in a twenty-year extension of the lease term. As a result, we remeasured the lease to include the extended lease term using an estimated incremental borrowing rate of 14.4 % , which resulted in increases to our right-of-use asset and lease liability of $0.1 million each.

Private Warrants

Private Warrants	9 Months Ended
	Sep. 30, 2023
Text Block [Abstract]
Private Warrants	Note 9. Private Warrants At September 30, 2023 and December 31, 2022, there were 3,914,525 outstanding warrants to purchase shares of our common stock at an exercise price of $ 11.50 per share, subject to adjustments, which were privately placed prior to the Business Combination ( “Private Warrants” ). The Private Warrants have been exercisable since May 7, 2021 . On December 28, 2025 , any then-outstanding Private Warrants will expire. The Private Warrants meet the definition of derivative instruments and are reported as liabilities at their fair values at each period end, with changes in the fair value of the Private Warrants recorded as a non-cash loss or gain. A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2022 $ ( 212 ) Loss on remeasurement of private warrants ( 1,116 ) Balance at March 31, 2023 ( 1,328 ) Gain on remeasurement of private warrants 1,083 Balance on June 30, 2023 ( 245 ) Gain on remeasurement of private warrants 132 Balance on September 30, 2023 $ ( 113 )

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Note 10. Debt The components of long-term debt were as follows: September 30, December 31, (in thousands) 2023 2022 3.25 % Convertible Senior Notes $ 240,000 $ 240,000 Senior Secured Term Loan 130,000 - New Market Tax Credit Transactions 45,700 45,700 Subordinated Term Loan - 10,205 Insurance Premium Finance Notes 1,066 1,828 Vehicle and Equipment Notes 352 366 Mortgage Notes 195 218 Total $ 417,313 $ 298,317 Less: Total unamortized debt issuance costs ( 37,442 ) ( 9,947 ) Less: Current maturities of long-term debt ( 1,184 ) ( 1,972 ) Total long-term debt $ 378,687 $ 286,398 3.25% Convertible Senior Notes On December 21, 2021, we issued $ 240 million principal amount of our 3.250 % Convertible Senior Notes due 2026 (“Convertible Notes”), subject to an indenture. The Convertible Notes are our senior, unsecured obligations and accrue interest at a rate of 3.250 % per annum, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2022. We will settle conversions by paying or delivering, as applicable, cash, shares of common stock or a combination of cash and shares, at our election. The initial conversion rate, which is subject to change, is approximately $ 10.79 per share of common stock. If certain liquidity conditions are met, we may redeem the Convertible Notes between December 19, 2024, and October 20, 2026. The Convertible Notes will mature on December 15, 2026. Capped Calls Also in December 2021, in connection with the Convertible Notes, we purchased capped calls (“Capped Calls”) with certain well-capitalized financial institutions for $ 35 million. The Capped Calls are call options that permit us, at our option, to require the counterparties to deliver to us shares of our common stock. We may also net-settle the Capped Calls and receive cash instead of shares. We have not exercised any of the Capped Calls at September 30, 2023, and the Capped Calls expire on April 12, 2027 . Senior Secured Term Loan On March 17, 2023, we closed a $ 130 million principal amount senior secured term loan (“Senior Secured Term Loan”). The Senior Secured Term Loan is secured by substantially all of our assets, other than the assets of Danimer Catalytic Technologies and assets associated with the Greenfield Facility. The Senior Secured Term Loan matures on the earlier of March 17, 2027 or September 15, 2026 if more than $ 100 million of the existing Convertible Notes remain outstanding on that date. After payment of the lender’s expenses, including the first three years of premiums for a collateral protection insurance policy for the benefit of the lender, we received net proceeds of $ 98.6 million. The Senior Secured Term Loan accrues interest at a stated annual rate of 14.4 % , payable monthly. As part of the Senior Secured Term Loan agreement, we are required to hold $ 12.5 million in an interest-payment reserve account, which we have reported as restricted cash. The Senior Secured Term Loan contains various customary covenants, which we do not expect to have a material impact on our liquidity or capital resources. The Senior Secured Term Loan required us to maintain a minimum cash balance of $ 45 million pending the receipt of certain consents, which were received during the second quarter of 2023. In connection with the Senior Secured Term Loan, we also issued warrants with a five-year maturity to the lender to purchase 1.5 million shares of our common stock at an exercise price of $ 7.50 per share. We determined the fair value of these warrants as of the closing date was $ 0.5 million using the Black-Scholes model, and included this amount in equity at September 30, 2023. Subordinated Term Loan In March 2019, we, through a subsidiary, entered into a subordinated credit agreement (“Subordinated Term Loan”) for $ 10 million in term loans. During 2023, we paid $ 10.2 million of principal and accrued interest, which repaid the entire balance of the loan. New Markets Tax Credit Transactions We entered into financing arrangements under the New Markets Tax Credit (“NMTC”) program with various unrelated third-party financial institutions (individually and collectively referred to as “Investors”), which then invest in certain “Investment Funds”. In these arrangements, we loaned money to the Investment Funds, which then contributed the funds from our loan and the Investor’s investment to special purpose entities, which then in turn loaned the contributed funds to wholly owned subsidiaries of the Company. We report the $ 31.4 million we loaned as leveraged loans receivable and report bank deposits of $ 1.9 million required under these NMTC arrangements for future interest and expense payments as restricted cash. We believe these borrowings, and our related loans to the Investment Funds, will be forgiven in 2026 and 2029. Insurance Premium Finance Notes In December 2022 and June 2023, we entered into financing agreements related to the premiums under certain insurance policies. These financing agreements had one year initial terms, and we make monthly payments on these notes at interest rates of 6.74 % and 8.24 % , respectively. Vehicle and Equipment Notes We have fourteen vehicle and equipment notes outstanding at September 30, 2023, primarily relating to motor vehicles and warehouse equipment. We make monthly payments on these notes at interest rates ranging from 3.75 % to 6.99 % . Mortgage Notes We have two mortgage notes secured by residential property. We make monthly payments on these notes at interest rates of 6.50% and 5.25% with maturity dates in October 2023 and March 2025. Cash Maturities As of September 30, 2023, the future cash maturities of long-term debt are as follows: (in thousands) Amount As of September 30, 2023 2023 $ 598 2024 623 2025 265 2026 261,087 2027 130,034 Thereafter 24,706 Total future maturities $ 417,313

Equity

Equity	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Equity	Note 11. Equity Common Stock The following table summarizes the common stock activity for the three and nine months ended September 30, 2023 and 2022, respectively. Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Balance, beginning of period 101,938,376 101,114,861 101,804,454 100,687,820 Issuance of common stock 96,891 273,812 230,813 700,853 Balance, end of period 102,035,267 101,388,673 102,035,267 101,388,673 Preferred Stock We are authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $ 0.0001 per share. As of September 30, 2023 and December 31, 2022, no shares of preferred stock were issued or outstanding. Non-Plan Legacy Danimer Options Prior to 2017, Legacy Danimer had issued 208,183 stock options that were not a part of either the 2016 Executive Plan or the 2016 Omnibus Plan. These options had a weighted average exercise price of $ 30 per share. On December 29, 2020, the then-remaining 30,493 of these options were converted to options to purchase 279,255 shares of our common stock with a weighted average exercise price of $ 3.28 per share. During 2021, 153,763 of these options were exercised. There were 125,492 of these options remaining outstanding at September 30, 2023 and December 31, 2022. Equity Distribution Agreement On September 7, 2022, we entered into an equity distribution agreement (“Equity Distribution Agreement”) with Citigroup Global Markets Inc. (“Manager”), under which we may issue and sell shares of our common stock “at the market” from time-to-time with an aggregate offering price of up to $ 100.0 million (collectively, “ATM Offering”). Under the Equity Distribution Agreement, the Manager may sell small volumes of our common stock at the prevailing market price, during such times and at such terms as we have predesignated. We have no obligation to sell any shares and may at any time suspend offers and sales that are part of the ATM Offering or terminate the Equity Distribution Agreement. During the year ended December 31, 2022, we issued 212,604 shares at an average price of $ 4.15 per share resulting in proceeds of $ 0.9 million. Additionally, we incurred issuance costs of $ 1.1 million, which were primarily one-time costs, but which also included less than $ 0.1 million in commissions to the Manager. As of September 30, 2023, $ 99.1 million remains available for distribution under the Equity Distribution Agreement. Anti-dilutive Instruments The following table summarizes the instruments excluded from the calculations of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Convertible debt 22,250,040 22,250,040 22,250,040 22,250,040 Employee stock options 11,900,448 11,877,355 11,900,448 11,877,355 Private Warrants 3,914,525 3,914,525 3,914,525 3,914,525 Restricted shares and RSUs 2,295,337 2,671,482 2,295,337 2,671,482 Senior Secured Term Loan Warrants 1,500,000 - 1,500,000 - Performance shares 127,770 50,251 127,770 50,251 Legacy Danimer options 125,492 125,492 125,492 125,492 Total excluded instruments 42,113,612 40,889,145 42,113,612 40,889,145 Senior Secured Term Loan Warrants On March 17, 2023, we issued warrants to purchase 1.5 million shares of our common stock for $ 7.50 per share in connection with the Senior Secured Term Loan. These warrants were accounted for as an equity arrangement and are included in additional paid-in-capital at September 30, 2023.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Note 12. Revenue We evaluate financial performance and make resource allocation decisions based upon the results of our single operating and reportable segment; however, we believe presenting revenue split between our primary revenue streams of products and services best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. We generally produce and sell finished products, for which we recognize revenue upon shipment. We provide for expected returns based on historical experience and future outlook. There are no forms of variable consideration such as discounts, rebates, or volume discounts that we estimate to reduce our transaction price. We defer certain contract fulfillment costs and amortize these costs to cost of revenue on a per-pound basis as we sell the related product or when the related contracts expire. During the three months ended September 30, 2023 and 2022, we expensed zero and $ 0.1 million, respectively. During the nine months ended September 30, 2023 and 2022, we expensed $ 1.1 million and $ 0.4 million, respectively. At September 30, 2023 and December 31, 2022, we had deferred aggregate contract fulfillment costs of $ 1.3 million and $ 3.2 million, respectively. Our research and development (“R&D”) services contract customers generally pay us at the commencement of the agreement and then at additional intervals as outlined in each contract. We recognize contract liabilities for such payments and then recognize revenue as we satisfy the related performance obligations. To the extent collectible revenue recognized under this method exceeds the consideration received, we recognize contract assets for such unbilled consideration. R&D contract assets, net were $4.0 million and $2.8 million at September 30, 2023 and December 31, 2022, respectively. Revenue recognized that was included in contract liabilities at the beginning of the period was not material for any period presented. Disaggregated Revenues Revenue by country is based on the location of the customer. The following table is a summary of revenue information by country. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 United States $ 10,771 $ 9,103 $ 33,565 $ 31,324 Poland 77 - 233 - Germany 6 - 1,349 2,694 Belgium 1 915 200 1,999 All other countries 93 430 392 1,877 Total revenues $ 10,948 $ 10,448 $ 35,739 $ 37,894

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Note 13. Stock-Based Compensation We grant various forms of stock-based compensation, including restricted stock, restricted stock units, stock options and performance-based restricted stock units under our Danimer Scientific, Inc. 2020 Long-Term Equity Incentive Plan (“2020 Incentive Plan”) and employee stock purchase plan instruments under our 2020 Employee Stock Purchase Plan (“2020 ESPP”). We also have outstanding employee and director stock options that were issued prior to the Business Combination under legacy stock plans. The 2020 Incentive Plan provides for the grant of stock options, stock appreciation rights, and full value awards. Full value awards include restricted stock, restricted stock units, deferred stock units, performance stock and performance stock units. On September 30, 2023 and December 31, 2022, 1,391,425 shares and 1,657,240 shares, respectively, of our common stock remained authorized for issuance with respect to awards under the 2020 Incentive Plan. The 2020 ESPP provides for the sale of our common stock to our employees through payroll withholding at a discount of 15 % from the lower of the closing price of our common stock on the first or last day of each biannual offering period. Up to 2,571,737 shares of our common stock were authorized to be issued under this plan. We have issued 182,037 shares during the nine months ended September 30, 2023 and 2,306,519 shares remain in the pool. These share pool limits are subject to adjustment in the event of a stock split, stock dividend or other changes in our capitalization. The following table sets forth the allocation of our stock-based compensation expense. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 2 $ 22 $ 6 $ 60 Selling, general and administrative 12,493 12,437 37,643 37,010 Research and development 1,829 1,846 5,284 5,480 Total stock-based compensation $ 14,324 $ 14,305 $ 42,933 $ 42,550 Service-based Restricted Stock and RSUs The following table summarizes our service-based restricted stock and RSU activity by quarter.  Number of Shares Weighted Average Grant-Date Balance, December 31, 2022 691,448 $ 28.51 Granted 6,250 $ 2.62 Vested ( 73,023 ) $ 5.86 Balance, March 31, 2023 624,675 $ 37.09 Granted 152,822 $ 3.01 Balance, June 30, 2023 777,497 $ 25.41 Balance, September 30, 2023 777,497 $ 25.41 We recognize the compensation expense for these shares on a straight-line basis from the grant date through the relevant vesting dates, which range from one to three years. We recognized expenses of $ 4.9 million related to these awards during each of the three months ended September 30, 2023 and 2022 and $ 14.1 million and $ 14.4 million during the nine months ended September 30, 2023 and 2022, respectively. Market-based Restricted Stock During 2021, we granted 1,517,840 shares of restricted stock for which the restrictions lapse on successive thirds of the award on the first date the volume-weighted average price per share of our common stock equals or exceeds $ 24.20 for any 20 trading dates within 30-day trading periods beginning on December 29, 2021, 2022, and 2023, respectively. We recognize the compensation expense for these shares on a straight-line basis from the grant date through January 2024. We recognized expenses of $ 4.6 million and $ 4.7 million during the three months ended September 30, 2023 and 2022, respectively, and $ 13.9 million during each of the nine months ended September 30, 2023 and 2022. As of September 30, 2023, all of these shares remained outstanding. Performance-based Restricted Stock On February 28, 2023, we awarded 462,519 shares of restricted stock with performance conditions. These shares are unvested until attainment of performance targets defined in the grant agreement as follows: • 50% of the shares are subject to a total PHA revenue metric based on 2025 financial results. 50% of these shares vest if total PHA revenue is $177 million, 100% vest if total PHA revenue is $202 million or higher, with prorated vesting between $ 177 million and $ 202 million . • 50% of the shares are subject to an Adjusted EBITDA Metric based on 2025 financial results. 50% of these shares vest if Adjusted EBITDA is $36 million, 100% vest if Adjusted EBITDA is $44 million or higher, with prorated vesting between $ 36 million and $ 44 million. On March 31, 2022, we awarded 489,949 shares of restricted stock with performance conditions. These shares are unvested until attainment of performance targets defined in the grant agreement as follows: • 30% of the shares are subject to a total PHA revenue metric based on 2024 financial results. 50% of these shares vest if total PHA revenue is $151 million, 100% vest if total PHA revenue is $189 million or higher, with prorated vesting between $ 151 million and $ 189 million. • 30% of the shares are subject to an Adjusted EBITDA Metric based on 2024 financial results. 50% of these shares vest if Adjusted EBITDA is $9.2 million, 100% vest if Adjusted EBITDA is $13.8 million or higher, with prorated vesting between $ 9.2 million and $ 13.8 million. • 40% of the shares are subject to a Neat PHA production capacity metric based on a third-party assessment at December 31, 2024, 50% of the shares vest if capacity is 68 million pounds, 100% vest if capacity is 81 million pounds or higher, with prorated vesting between 68 million pounds and 81 million pounds. On July 23, 2021, we awarded 95,943 shares of restricted stock with performance conditions. These shares are unvested until attainment of performance targets defined in the grant agreement as follows: • 30% of the shares are subject to a return on equity “ROE” metric based on 2023 financial results. 50% of these shares vest if ROE is 5%, 100% vest if ROE is 9% or higher, with prorated vesting between 5 % and 9 %. • 3 0% of the shares are subject to an EBITDA Metric based on 2023 financial results. 50% of these shares vest if EBITDA is $ 45 million, 100% vest if EBITDA is $ 65 million or higher, with prorated vesting between $ 45 million and $ 65 million. • 40% of the shares are subject to a Neat PHA production capacity metric based on a third-party assessment at December 31, 2023, 50% of the shares vest if capacity is 75 million pounds, 100% vest if capacity is 90 million pounds or higher, with prorated vesting between 75 million pounds and 90 million pounds. In addition to these performance conditions, vesting of certain of these shares are also subject to having sufficient capacity in the 2020 Incentive Plan, which may not have enough shares remaining to fulfill these awards. In the event registered shares are unavailable, 920,641 of the 1,048,411 outstanding performance shares must be settled in cash as calculated using the price of our common stock on the vesting date. Due to this cash settlement feature, certain performance shares are accounted for as a liability. At September 30, 2023, the balance of this liability was $ 0.6 million. These performance shares are marked to market using the price of our common stock with a life-to-date adjustment. Other than this mark to market effect, expense is recognized on a straight-line basis between the dates of grant and the vesting dates, which we anticipate will be in February 2024, March 2025 and February 2026, respectively. We are currently assuming 100% attainment of our 2024 and 2025 metrics and 0% attainment of our 2023 metrics. As a result, we have reversed all expense associated with the July 23, 2021 award. During the three months and nine months ended September 30, 2023, we recognized selling, general and administrative expenses of $ 0.1 million and $ 0.5 million, respectively, related to these performance shares. All of these performance shares remained outstanding at September 30, 2023. Stock Options A summary of stock option activity under our equity plans for the three and nine months ended September 30, 2023 follows:  Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance, December 31, 2022 11,844,644 $ 14.23 6.71 $ - Granted 204,254 $ 2.58 Forfeited ( 4,667 ) Balance, March 31, 2023 12,044,231 $ 14.04 6.48 $ 852,617 Forfeited ( 93,633 ) Balance, June 30, 2023 11,950,598 $ 14.02 6.22 $ - Forfeited ( 50,150 ) Balance, September 30, 2023 11,900,448 $ 14.02 5.96 $ - Exercisable 5,217,843 $ 5.00 4.08 $ - Vested and expected to vest 11,900,448 $ 14.02 5.96 $ - The aggregate intrinsic values are calculated as the difference between the exercise price of the indicated stock options and the fair value of our common stock on each applicable balance sheet date. In addition to the stock options granted under our equity plans, during the quarters ended March 31, 2023 and 2022, we granted 1,050,000 and 972,222 stock options, respectively, that contained a cash-settlement feature if adequate shares were not available to settle the award by the vesting dates. For the nine months ended September 30, 2023, we recognized expense of $ 0.4 million and maintained a long-term liability of $ 0.5 million related to these stock options. There were no options granted during the three month period ended September 30, 2023 and 146,666 options granted in the three month period ended September 30, 2022. The weighted average grant-date fair values of options granted during the three month period ended September 30, 2022, was $ 1.97 . As of September 30, 2023, there was $ 17.8 million of unrecognized compensation cost related to unvested stock options and restricted shares granted under the 2020 Incentive Plan. That cost is expected to be recognized over a weighted-average period of 1.5 years.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Commitments In connection with our 2007 acquisition of certain intellectual property, we agreed to pay royalties to Procter & Gamble upon production and sale of PHA. The royalty was $ 0.05 per pound for the first 500 million pounds of PHA sold and decreased to $ 0.025 per pound for cumulative sales in excess of that amount until the underlying patents expire. In 2023, we terminated this royalty agreement. We retained all intellectual property associated with the agreement but forfeited related prepaid royalties, which resulted in a loss of $ 0.5 million in the nine months ended September 30, 2023. Litigation Matters On May 14, 2021, a class action complaint was filed by Darryl Keith Rosencrants in the United States District Court for the Eastern District of New York, on May 18, 2021, a class action complaint was filed by Carlos Caballeros in the United States District Court for the Middle District of Georgia, on May 18, 2021, a class action complaint was filed by Dennis H. Wilkins also in the United States District Court for the Middle District of Georgia, and on May 19, 2021, a class action complaint was filed by Elizabeth and John Skistimas in the United States District Court for the Eastern District of New York. Each plaintiff or plaintiffs brought the action individually and on behalf of all others similarly situated against the Company. The alleged class varies in each case but covers all persons and entities other than Defendants who purchased or otherwise acquired our securities between October 5, 2020 and May 4, 2021 (“Class Period”). Plaintiffs are seeking to recover damages caused by Defendants’ alleged violations of the federal securities laws and are pursuing remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and Rule 10b-5 promulgated thereunder. The complaints are substantially similar and are each premised upon various allegations that throughout the Class Period, Defendants made materially false and misleading statements regarding, among other things, our business, operations and compliance policies. Plaintiffs seek the following remedies: (i) determining that the lawsuits may be maintained as class actions under Rule 23 of the Federal Rules of Civil Procedure, (ii) certifying a class representative, (iii) requiring Defendants to pay damages allegedly sustained by plaintiffs and the class members by reason of the acts alleged in the complaints, and (iv) awarding pre-judgment and post-judgment interest as well as reasonable attorneys’ fees, expert fees and other costs. On July 29, 2021, the Georgia court transferred the Georgia cases to New York, and all four class actions have been consolidated into a single lawsuit in the Eastern District of New York. On January 19, 2022, a Consolidated Amended Class Action Complaint (“Amended Complaint”) was filed in the Eastern District of New York, naming as defendants the Company, its directors and certain of its officers as well as certain former directors (collectively, “Defendants”). The Amended Complaint is brought on behalf of a class consisting of (i) purchasers of shares of the Company during the Class Period, (ii) all holders of the Company’s Class A common stock entitled to vote on the merger transaction between the Company and Meredian Holdings Group, Inc. consummated on December 28, 2020 and (iii) purchasers of Company securities pursuant to the Company’s Registration Statement on Form S-4 that was declared effective on December 16, 2020 or the Company’s Registration Statement on Form S-1 that was declared effective on February 16, 2021. The Amended Complaint asserts claims for violations of Sections 10(b), 14(a) and 20(a) of the Exchange Act and Rules 10(b)-5(a)-(c) promulgated thereunder and Sections 11, 12 and 15 of the Securities Act of 1933, as amended (the “Securities Act”). Plaintiffs seek the following remedies: (a) a determination that the lawsuit is a proper class action pursuant to Rule 23 of the Federal Rules of Civil Procedure and certifying Plaintiffs as class representative, (b) awarding compensatory and punitive damages allegedly sustained by the class members by reason of the acts set forth in the Amended Complaint and (c) awarding pre-judgment and post-judgment interest and costs and expenses, including reasonable attorneys’ fees, experts’ fees and other costs. On September 30, 2023, the court issued an Order granting Defendant’s motion to dismiss in full, dismissing Plaintiffs’ claims with prejudice, and denying Plaintiffs’ request for leave to amend. On October 27, 2023, the Plaintiffs filed a notice of appeal. On May 24, 2021, a shareholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware by Richard Delman on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. On October 6, 2021, a shareholder derivative lawsuit was filed in the United States District Court for the District of Delaware by Ryan Perri on behalf of the Company, alleging breach of fiduciary duty against the Company’s directors. On February 9, 2023, a shareholder derivative lawsuit was filed in the United States District Court for the District of Delaware by Samuel Berezin on behalf of the Company, alleging breach of fiduciary trust against the Company’s directors. All three shareholder derivative lawsuits have been stayed pending the outcome of Defendants’ motion to dismiss the securities class actions. These derivative complaints repeat certain allegations which are already in the public domain. Defendants deny the allegations of the above complaints, believe the lawsuits are without merit and intend to defend them vigorously. Since we are unable to estimate the likelihood of incurring a loss, or the amount of loss, if any, related to these matters, we have not accrued any losses for these matters at September 30, 2023. On May 5, 2021, we received a letter from the Atlanta regional office of the SEC, in connection with a non-public, fact-finding inquiry, requesting that we voluntarily produce certain specified information, to which we timely and voluntarily produced the requested information on July 14, 2021. Subsequently, the SEC had additional follow-up requests for further information, and we have timely and voluntarily responded to all such requests. In the ordinary course of business, we may be a party to various other legal proceedings from time to time.

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Considerations [Abstract]
Schedule of ranges of values used and fair value determined	The following table sets forth the ranges of calculated fair values and the associated ranges of values we used for remeasurement in our Black-Scholes calculations for stock options, other than ESPP. Three Months Ended September 30, 2023 2022 Share prices of our common stock $ 2.07 $ 2.95 - $ 4.81 Expected volatilities 51.76 % - 55.88 % 47.55 % - 49.38 % Risk-free rates of return 4.50 % - 4.61 % 2.93 % - 4.00 % Expected option terms (years) 3.82 - 5.42 4.81 - 6.00 Calculated option values $ 0.04 -$ 0.95 $ 0.12 - $ 2.25 The following table sets forth the fair values we calculated and the inputs we used in our Black-Scholes models for Private Warrants. September 30, December 31, 2023 2022 Share prices of our common stock $ 2.07 $ 1.79 Expected volatilities 53.33 % 55.83 % Risk-free rates of return 4.92 % 4.13 % Expected warrant term (years) 2.25 3.00 Calculated Private Warrant values $ 0.03 $ 0.05

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories, net consisted of the following: September 30, December 31, (in thousands) 2023 2022 Raw materials $ 10,936 $ 19,964 Work in process 762 1,524 Finished goods and related items 14,987 11,255 Total inventories, net $ 26,685 $ 32,743

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: September 30, December 31, (in thousands) Estimated Useful Life (Years) 2023 2022 Land and improvements 20 $ 92 $ 92 Leasehold improvements Shorter of useful life or lease term 110,387 109,805 Buildings 15 - 40 2,191 2,156 Machinery and equipment 5 - 20 183,797 180,846 Motor vehicles 7 - 10 921 921 Furniture and fixtures 7 - 10 474 473 Office equipment 3 - 10 6,871 5,976 Construction in progress N/A 208,367 198,545 513,100 498,814 Accumulated depreciation and amortization ( 63,276 ) ( 44,865 ) Property, plant and equipment, net $ 449,824 $ 453,949
Schedule of depreciation and amortization expense	We reported depreciation and amortization expense (including amortization of intangible assets) as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 5,086 $ 2,571 $ 15,233 $ 7,087 Research and development 1,865 1,839 5,903 5,587 Selling, general and administrative 302 175 869 498 Total depreciation and amortization expense $ 7,253 $ 4,585 $ 22,005 $ 13,172
Schedule of Construction in Progress	Construction in progress consists primarily of the early phases of construction of our PHA plant in Bainbridge, Georgia (“Greenfield Facility”) and construction of a Rinnovo pilot plant in Rochester, New York as noted in the table below. (in thousands) September 30, December 31, Georgia $ 199,940 $ 191,576 New York 6,753 4,959 Kentucky 1,674 2,010 $ 208,367 $ 198,545

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets net	Intangible assets, net, consisted of the following: September 30, December 31, (in thousands) 2023 2022 Intangible assets, gross $ 95,565 $ 94,291 Less capitalized patent costs not yet subject to amortization ( 2,682 ) ( 1,604 ) Intangible assets subject to amortization, gross 92,883 92,687 Accumulated amortization, beginning balance ( 13,350 ) ( 8,585 ) Amortization in the quarter ended: March 31 ( 1,203 ) ( 1,181 ) June 30 ( 1,205 ) ( 1,186 ) September 30 ( 1,147 ) ( 1,185 ) December 31 - ( 1,213 ) Accumulated amortization, ending balance ( 16,905 ) ( 13,350 ) Intangible assets subject to amortization, net 75,978 79,337 Total intangible assets, net $ 78,660 $ 80,941

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of accrued liabilities	The components of accrued liabilities were as follows: September 30, December 31, (in thousands) 2023 2022 Accrued interest $ 2,390 $ 134 Compensation and related expenses 1,352 1,305 Accrued taxes 1,002 669 Accrued utilities 304 415 Accrued legal, professional and consulting fees 286 443 Construction in progress accruals 94 1,089 Purchase accrual 31 401 Other 440 545 Total accrued liabilities $ 5,899 $ 5,001

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure Text Block [Abstract]
Schedule of operating lease costs	The following table sets forth the allocation of our operating lease costs. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 673 $ 626 $ 1,927 $ 1,880 Research and development 457 113 668 423 Selling, general and administrative ( 179 ) 136 101 333 Total operating lease cost $ 951 $ 875 $ 2,696 $ 2,636 We currently lease our facility in Winchester, Kentucky and certain facilities in Bainbridge, Georgia under an operating lease. As of December 31, 2022, the lease had a remaining term of 16 years. During the nine months ended September 30, 2023, we concluded that it is reasonably certain that we will exercise our four, five-year extension options under the lease, resulting in a twenty-year extension of the lease term. As a result, we remeasured the lease to include the extended lease term using an estimated incremental borrowing rate of 14.4 % , which resulted in increases to our right-of-use asset and lease liability of $0.1 million each.

Private Warrants (Tables)

Private Warrants (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Measurement Inputs and Valuation Techniques [Abstract]
Schedule of private warrant liability	A rollforward of the Private Warrants liability is below. (in thousands) Balance at December 31, 2022 $ ( 212 ) Loss on remeasurement of private warrants ( 1,116 ) Balance at March 31, 2023 ( 1,328 ) Gain on remeasurement of private warrants 1,083 Balance on June 30, 2023 ( 245 ) Gain on remeasurement of private warrants 132 Balance on September 30, 2023 $ ( 113 )

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of long-term debt	The components of long-term debt were as follows: September 30, December 31, (in thousands) 2023 2022 3.25 % Convertible Senior Notes $ 240,000 $ 240,000 Senior Secured Term Loan 130,000 - New Market Tax Credit Transactions 45,700 45,700 Subordinated Term Loan - 10,205 Insurance Premium Finance Notes 1,066 1,828 Vehicle and Equipment Notes 352 366 Mortgage Notes 195 218 Total $ 417,313 $ 298,317 Less: Total unamortized debt issuance costs ( 37,442 ) ( 9,947 ) Less: Current maturities of long-term debt ( 1,184 ) ( 1,972 ) Total long-term debt $ 378,687 $ 286,398
Schedule of future maturities of long-term debt	As of September 30, 2023, the future cash maturities of long-term debt are as follows: (in thousands) Amount As of September 30, 2023 2023 $ 598 2024 623 2025 265 2026 261,087 2027 130,034 Thereafter 24,706 Total future maturities $ 417,313

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Summary of the common stock activity	The following table summarizes the common stock activity for the three and nine months ended September 30, 2023 and 2022, respectively. Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Balance, beginning of period 101,938,376 101,114,861 101,804,454 100,687,820 Issuance of common stock 96,891 273,812 230,813 700,853 Balance, end of period 102,035,267 101,388,673 102,035,267 101,388,673 Preferred Stock We are authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $ 0.0001 per share. As of September 30, 2023 and December 31, 2022, no shares of preferred stock were issued or outstanding.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table summarizes the instruments excluded from the calculations of diluted shares outstanding because the effect of including them would have been anti-dilutive. Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Convertible debt 22,250,040 22,250,040 22,250,040 22,250,040 Employee stock options 11,900,448 11,877,355 11,900,448 11,877,355 Private Warrants 3,914,525 3,914,525 3,914,525 3,914,525 Restricted shares and RSUs 2,295,337 2,671,482 2,295,337 2,671,482 Senior Secured Term Loan Warrants 1,500,000 - 1,500,000 - Performance shares 127,770 50,251 127,770 50,251 Legacy Danimer options 125,492 125,492 125,492 125,492 Total excluded instruments 42,113,612 40,889,145 42,113,612 40,889,145

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Disaggregation of Revenue [Abstract]
Schedule of revenue information by major geographic area	Revenue by country is based on the location of the customer. The following table is a summary of revenue information by country. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 United States $ 10,771 $ 9,103 $ 33,565 $ 31,324 Poland 77 - 233 - Germany 6 - 1,349 2,694 Belgium 1 915 200 1,999 All other countries 93 430 392 1,877 Total revenues $ 10,948 $ 10,448 $ 35,739 $ 37,894

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of stock option activity under our equity plans	A summary of stock option activity under our equity plans for the three and nine months ended September 30, 2023 follows:  Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance, December 31, 2022 11,844,644 $ 14.23 6.71 $ - Granted 204,254 $ 2.58 Forfeited ( 4,667 ) Balance, March 31, 2023 12,044,231 $ 14.04 6.48 $ 852,617 Forfeited ( 93,633 ) Balance, June 30, 2023 11,950,598 $ 14.02 6.22 $ - Forfeited ( 50,150 ) Balance, September 30, 2023 11,900,448 $ 14.02 5.96 $ - Exercisable 5,217,843 $ 5.00 4.08 $ - Vested and expected to vest 11,900,448 $ 14.02 5.96 $ -
Schedule of share based compensation activity	The following table sets forth the allocation of our stock-based compensation expense. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 2 $ 22 $ 6 $ 60 Selling, general and administrative 12,493 12,437 37,643 37,010 Research and development 1,829 1,846 5,284 5,480 Total stock-based compensation $ 14,324 $ 14,305 $ 42,933 $ 42,550
Schedule of option award on the date of grant using the Black-Scholes option	The following table summarizes our service-based restricted stock and RSU activity by quarter.  Number of Shares Weighted Average Grant-Date Balance, December 31, 2022 691,448 $ 28.51 Granted 6,250 $ 2.62 Vested ( 73,023 ) $ 5.86 Balance, March 31, 2023 624,675 $ 37.09 Granted 152,822 $ 3.01 Balance, June 30, 2023 777,497 $ 25.41 Balance, September 30, 2023 777,497 $ 25.41

Basis of Presentation (Addition

Basis of Presentation (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Description of Business and Basis of Presentation (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001		$ 0.0001
Net loss and comprehensive (loss) income	$ 0	$ 0

Business Combination (Additiona

Business Combination (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Business Combination (Details) [Line Items]
Net loss	$ (40,159)	$ (94,876)	$ (116,039)	$ (151,707)
Right-of-use assets	$ 19,157		$ 19,157		$ 19,028

Fair Value Considerations (Addi

Fair Value Considerations (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant-date fair value of options granted (in Dollars per share)		$ 1.97
Secured Long-Term Debt, Noncurrent			$ 87.3	$ 45
Fair value of convertible debt			$ 78.3
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Remaining stock, closing price			$ 2.07
Weighted average grant-date fair value of options granted (in Dollars per share)	$ 2.62

Fair Value Considerations - Sch

Fair Value Considerations - Schedule of ranges of values used and fair value determined (Details) - Black-Scholes [Member] - $ / shares	3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Dec. 31, 2022
Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected Volatility Rate, Maximum	55.88%	49.38%
Expected Volatility Rate, Minimum	51.76%	47.55%
Risk Free Interest Rate, Maximum	4.61%	4%
Risk Free Interest Rate, Minimum	4.50%	2.93%
Stock Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock		$ 4.81
Expected term (years)	5 years 5 months 1 day	6 years
Stock Option [Member] | Maximum [Member] | Danimer Black Sholes [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Calculated option values, Maximum	$ 0.95	$ 2.25
Stock Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock	$ 2.07	$ 2.95	$ 2.07
Expected term (years)	3 years 9 months 25 days	4 years 9 months 21 days
Stock Option [Member] | Minimum [Member] | Danimer Black Sholes [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Calculated option values, Minimum	$ 0.04	$ 0.12
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share prices of our common stock	$ 2.07		$ 2.07	$ 1.79
Expected volatility			53.33%	55.83%
Risk-free rate of return			4.92%	4.13%
Expected term (years)			2 years 3 months	3 years
Warrant [Member] | Danimer Black Sholes [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value determined per warrant			$ 0.03	$ 0.05

Restricted Cash - Schedule of R

Restricted Cash - Schedule of Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents Items [Line Items]
Total cash and cash equivalents and restricted cash	$ 91,854	$ 64,401	$ 100,790	$ 286,968

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of inventory [Abstract]
Raw materials	$ 10,936	$ 19,964
Work in progress	762	1,524
Finished goods and related items	14,987	11,255
Total inventories, net	$ 26,685	$ 32,743

Inventories (Additional Informa

Inventories (Additional Information) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Inventory, Net [Abstract]
Finished neat PHA included in finished goods	$ 8.8	$ 4.9
Inventory reserves fair value	$ 0.5

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - Schedule of Property, plant, and equipment, net - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 513,100	$ 498,814
Accumulated depreciation and amortization	(63,276)	(44,865)
Property, plant and equipment, net	$ 449,824	453,949
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Property and equipment, gross	$ 92	92
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	110,387	109,805
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,191	2,156
Buildings [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	15 years
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	40 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 183,797	180,846
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 921	921
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 474	473
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 6,871	5,976
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 208,367	$ 198,545

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of depreciation and amortization expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	$ 7,253	$ 4,585	$ 22,005	$ 13,172
Cost of revenue [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	5,086	2,571	15,233	7,087
Selling, general, and administrative [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	302	175	869	498
Research & development [Member]
Property, Plant and Equipment, net (Details) - Schedule of depreciation and amortization expense [Line Items]
Total depreciation and amortization expense	$ 1,865	$ 1,839	$ 5,903	$ 5,587

Property, Plant and Equipment -

Property, Plant and Equipment - construction in prog (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	$ 208,367	$ 198,545
Georgia Member
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	199,940	191,576
New York Member
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	6,753	4,959
Kentucky Member
Property, Plant and Equipment, Gross [Abstract]
Construction in Progress, Gross	$ 1,674	$ 2,010

Property, Plant and Equipment_4

Property, Plant and Equipment (Additional Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant, and equipment includes capitalized interest	$ 14.9		$ 14.9		$ 14.6
Property, plant and equipment interest costs	$ 0.1	$ 2	0.3	$ 3.6
Maximum [Member]
Property, Plant and Equipment [Line Items]
Engineering Cost			665
Minimum [Member]
Property, Plant and Equipment [Line Items]
Engineering Cost			$ 515

Intangible Assets (Additional I

Intangible Assets (Additional Information) (Details)	9 Months Ended
	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	17 years 9 months 18 days
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	20 years
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	13 years

Intangible Assets - Schedule of

Intangible Assets - Schedule of intangible assets net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 95,565	$ 94,291
Less capitalized patent costs not yet subject to amortization	(2,682)	(1,604)
Intangible assets subject to amortization, gross	92,883	92,687
Amortization in the quarter ended	(16,905)	(13,350)	$ (8,585)
Intangible assets subject to amortization, net	75,978	79,337
Total intagible assets, net	78,660	80,941
March 31 [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization in the quarter ended	(1,203)	(1,181)
June 30 [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization in the quarter ended	(1,205)	(1,186)
September 30 [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization in the quarter ended	0	(1,185)
December 31 [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization in the quarter ended	$ 0	$ (1,213)

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of accrued liabilities [Abstract]
Accrued interest	$ 2,390	$ 134
Compensation and related expenses	1,352	1,305
Accrued taxes	1,002	669
Accrued utilities	304	415
Accrued legal, professional and consulting fees	286	443
Construction in progress accruals	94	1,089
Purchase accrual	31	401
Other	440	545
Total accrued liabilities	$ 5,899	$ 5,001

New Markets Tax Credit Transact

New Markets Tax Credit Transactions (Details)	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Interest rate	8.24%	6.74%

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income taxes	$ 468	$ (236)	$ 317	$ (767)
Effective tax rates	1.18%	0.25%	0.27%	0.50%
Statutory rate			21%

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Operating Lease, Liability [Abstract]
Remaining Lease Term		16 years
Incremental borrowing rate percentage	14.40%
Right-of-use assets	$ 19,157	$ 19,028

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease costs - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ 951	$ 875	$ 2,696	$ 2,636
Cost of revenue [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	673	626	1,927	1,880
Research and development [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	457	113	668	423
Selling, general and administrative [Member]
Operating Leases (Details) - Schedule of operating lease costs [Line Items]
Total operating lease cost	$ (179)	$ 136	$ 101	$ 333

Private Warrants - Additional I

Private Warrants - Additional Information (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	3,914,525	3,914,525
Class of Warrant or Right, Date from which Warrants or Rights Exercisable	May 07, 2021
Private Warrants
Class of Warrant or Right [Line Items]
Warrant price per share	$ 11.5	$ 11.5
Warrants and Rights Outstanding, Maturity Date	Dec. 28, 2025

Private Warrants - Summary of R

Private Warrants - Summary of Rollforward of Private Warrants Liability (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Balance			$ (212)		$ (212)
Gain on remeasurement of private warrants	$ (132)			$ (1,607)	(99)	$ (8,614)
Balance	(113)				(113)
Private Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Balance	(245)	$ (1,328)	(212)		(212)
Gain on remeasurement of private warrants	132	1,083	(1,116)
Balance	$ (113)	$ (245)	$ (1,328)		$ (113)

Debt (Details) - Schedule of lo

Debt (Details) - Schedule of long-term debt - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	$ 417,313	$ 298,317
Less: Total unamortized debt issuance costs	(37,442)	(9,947)
Less: Current maturities of debt issuance costs	(1,184)	(1,972)
Total long-term debt	378,687	286,398
Convertible Debt Note [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	240,000	240,000
Senior Secured Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	130,000	0
NMTC Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	45,700	45,700
Subordinated Term Loan [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	0	10,205
Insurance Premium Finance Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	1,066	1,828
Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	352	366
Mortgage Notes [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Total future maturities	$ 195	$ 218

Debt Schedule of long-term debt

Debt Schedule of long-term debt - Parenthetical (Details)	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Interest rate		8.24%	6.74%
Convertible Debt Note [Member]
Long-Term Debt (Details) - Schedule of long-term debt [Line Items]
Interest rate	3.25%

Debt (Details)

Debt (Details) $ / shares in Units, $ in Thousands				3 Months Ended		9 Months Ended
	Mar. 17, 2023 USD ($) $ / shares shares	Dec. 21, 2021 USD ($)	Dec. 16, 2021 USD ($)	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($) shares	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 Numbers	Dec. 31, 2021 USD ($) $ / shares	Mar. 31, 2019 USD ($)
Long-Term Debt (Details) [Line Items]
Convertible senior notes due year		2026
Accrued interest				$ 2,390		$ 2,390			$ 134
Unrestricted cash on deposit				77,393		77,393			62,792
Leverage loans receivable				31,446		31,446			31,446
Bank Deposits				1,900		1,900
Gain on forgiveness of debt				0	$ 1,500	102	$ 1,500
Minimum cash required				91,854	100,790	91,854	100,790		$ 64,401		$ 286,968
Fair value of warrants				(132)	$ (1,607)	(99)	$ (8,614)
Senior secured term loan, minimum cash balance				$ 87,300		$ 87,300		$ 45,000
Issuance of common stock | shares				96,891	273,812	230,813	700,853
Interest rate								8.24%	6.74%
Conversion price per share (in Dollars per share) | $ / shares											$ 10.79
2019 Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Subordinated term loan				$ 10,200		$ 10,200						$ 10,000
Senior Notes [Member]
Long-Term Debt (Details) [Line Items]
Convertible senior notes issued		$ 240,000
Interest rate		3.25%
Senior Secured Term Loan [Member]
Long-Term Debt (Details) [Line Items]
Principal amount	$ 130,000
Fair value of warrants	$ 500
Warrant price per share | $ / shares	$ 7.5
Issuance of common stock | shares	1,500,000
Interest rate	14.40%
Restricted cash	$ 12,500
Proceeds from loan	98,600
Note payable outstanding amount	$ 100,000
Convertible Debt Note [Member]
Long-Term Debt (Details) [Line Items]
Interest rate				3.25%		3.25%
Mortgage Notes [Member]
Long-Term Debt (Details) [Line Items]
Number Of Notes | Numbers										2
Debt instrument, maturity date, description						notes at interest rates of 6.50% and 5.25% with maturity dates in October 2023 and March 2025.
Minimum [Member] | Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate				3.75%		3.75%
Maximum [Member] | Vehicle and Equipment Notes [Member]
Long-Term Debt (Details) [Line Items]
Interest rate				6.99%		6.99%
Capped Call Options [Member]
Long-Term Debt (Details) [Line Items]
Purchase of capped call options			$ 35,000
Capped calls expire date						Apr. 12, 2027

Debt - Schedule of future matur

Debt - Schedule of future maturities of long-term debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of future maturities of long-term debt [Abstract]
2023	$ 598
2024	623
2025	265
2026	261,087
2027	130,034
Thereafter	24,706
Total future maturities	$ 417,313	$ 298,317

Equity - Summary of the common

Equity - Summary of the common stock activity (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Balance, beginning of period	101,938,376	101,114,861	101,804,454	100,687,820
Issuance of common stock	96,891	273,812	230,813	700,853
Balance, end of period	102,035,267	101,388,673	102,035,267	101,388,673

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 17, 2023	Dec. 29, 2020	Mar. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2016	Sep. 07, 2022
Stockholders' Equity (Details) [Line Items]
Preferred stock, authorized (in Shares)				10,000,000
Preferred share, par value				$ 0.0001
Preferred stock, shares outstanding				0	0
Preferred stock, shares issued				0	0
Common stock, shares authorized				200,000,000	200,000,000
Outstanding warrants (in Shares)				3,914,525	3,914,525
Options issued			204,254
Number of shares, exercised				(125,492)	(125,492)
Legacy Danimer options
Stockholders' Equity (Details) [Line Items]
Options issued							208,183
Weighted Average Exercise Price of per share (in Dollars per share)		$ 30
Number of shares, exercised						(153,763)
Exercisable and remained outstanding ( in shares)		30,493
Conversion of Stock, Shares Issued		279,255
Weighted Average Exercise Price, Exercised (in Dollars per share)		$ 3.28
Equity Distribution Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Stock issued					212,604
Value of stock issued					$ 0.9
Related to equity issuance					1.1
Payments for Commissions					$ 0.1
Cash Available for Distributions				$ 99.1
Weighted Average Exercise Price, Exercised (in Dollars per share)					$ 4.15
Senior Loans [Member]
Stockholders' Equity (Details) [Line Items]
Price per share (in Dollars per share)	$ 7.5
Conversion of Stock, Shares Issued	1,500,000
Common Class A [Member] | Equity Distribution Agreement [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized								100,000,000

Equity Antidilutive Securities

Equity Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	42,113,612	40,889,145	42,113,612	40,889,145
Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	22,250,040	22,250,040	22,250,040	22,250,040
Employee Stock Option Member
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,900,448	11,877,355	11,900,448	11,877,355
Private Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,914,525	3,914,525	3,914,525	3,914,525
Restricted Shares and RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,295,337	2,671,482	2,295,337	2,671,482
Senior Secured Term Loan Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,500,000	0	1,500,000	0
Performance shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	127,770	50,251	127,770	50,251
Legacy Danimer options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	125,492	125,492	125,492	125,492

Revenue (Additional Information

Revenue (Additional Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Fulfillment costs to cost of revenue	$ 0	$ 0.1	$ 1.1	$ 0.4
Contract assets recorded related to fulfillment costs	$ 1.3		$ 1.3		$ 3.2

Revenue - Change in Contract As

Revenue - Change in Contract Asset and Contract Liability Balance (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contract asset reserve	$ 0	$ (1,215)

Revenue - Summary of Revenue In

Revenue - Summary of Revenue Information by Major Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 10,948	$ 10,448	$ 35,739	$ 37,894
United States
Disaggregation of Revenue [Line Items]
Total revenue	10,771	9,103	33,565	31,324
Poland
Disaggregation of Revenue [Line Items]
Total revenue	77	0	233	0
Germany
Disaggregation of Revenue [Line Items]
Total revenue	6	0	1,349	2,694
Belgium
Disaggregation of Revenue [Line Items]
Total revenue	1	915	200	1,999
All Other Countries
Disaggregation of Revenue [Line Items]
Total revenue	$ 93	$ 430	$ 392	$ 1,877

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended					9 Months Ended		12 Months Ended
	Feb. 28, 2023	Jul. 23, 2021	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2022
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units			96,891			273,812		230,813	700,853
Issuance of common stock			96,891			273,812		230,813	700,853
Weighted average grant-date fair value of options granted (in Dollars per share)						$ 1.97
Number of Shares, Granted					204,254
Unrecognized compensation cost related to nonvested stock options grant (in Dollars)			$ 17,800					$ 17,800
Weighted-average over period								1 year 6 months
Selling, general and administrative			16,555			$ 19,413		$ 52,098	$ 62,042
Stock-based compensation expense								42,227	42,398
Third anniversary [Member]
Stock-Based Compensation (Details) [Line Items]
Share prices of our common stock											$ 24.2
Common stock equals or exceeds (in Dollars per share)											$ 24.2
Neat PHA Production Capacity Metric [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value		$ 90,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)		90,000
Neat PHA Production Capacity Metric [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value		75,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)		$ 75,000
Restricted Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Weighted average grant-date fair value of options granted (in Dollars per share)					$ 2.62
Number of Shares, Granted				152,822	6,250
Stock-based compensation expense			4,900			$ 4,900		$ 14,100	14,400
Performance Shares [Member]
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units								1,048,411
Issuance of common stock								1,048,411
Restricted stock shares	462,519	95,943					489,949
Long term liability			600					$ 600
Performance Shares [Member] | Selling, general and administrative [Member]
Stock-Based Compensation (Details) [Line Items]
Stock-based compensation expense			$ 100					500
Performance Shares [Member] | ROE [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description		30% of the shares are subject to a return on equity “ROE” metric based on 2023 financial results. 50% of these shares vest if ROE is 5%, 100% vest if ROE is 9% or higher, with prorated vesting between 5% and 9%.
Performance Shares [Member] | ROE [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting percentage		9%
Performance Shares [Member] | ROE [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting percentage		5%
Performance Shares [Member] | EBITDA Metric [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description	50% of the shares are subject to an Adjusted EBITDA Metric based on 2025 financial results. 50% of these shares vest if Adjusted EBITDA is $36 million, 100% vest if Adjusted EBITDA is $44 million or higher, with prorated vesting between $36 million and $44 million.	0% of the shares are subject to an EBITDA Metric based on 2023 financial results. 50% of these shares vest if EBITDA is $45 million, 100% vest if EBITDA is $65 million or higher, with prorated vesting between $45 million and $65 million.					30% of the shares are subject to an Adjusted EBITDA Metric based on 2024 financial results. 50% of these shares vest if Adjusted EBITDA is $9.2 million, 100% vest if Adjusted EBITDA is $13.8 million or higher, with prorated vesting between $9.2 million and $13.8 million.
Performance Shares [Member] | EBITDA Metric [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	$ 44,000	$ 65,000					$ 13,800
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	44,000	65,000					13,800
Performance Shares [Member] | EBITDA Metric [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	36,000	45,000					9,200
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	$ 36,000	$ 45,000					$ 9,200
Performance Shares [Member] | Neat PHA Production Capacity Metric [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description	50% of the shares are subject to a total PHA revenue metric based on 2025 financial results. 50% of these shares vest if total PHA revenue is $177 million, 100% vest if total PHA revenue is $202 million or higher, with prorated vesting between $177 million and $202 million	40% of the shares are subject to a Neat PHA production capacity metric based on a third-party assessment at December 31, 2023, 50% of the shares vest if capacity is 75 million pounds, 100% vest if capacity is 90 million pounds or higher, with prorated vesting between 75 million pounds and 90 million pounds.					40% of the shares are subject to a Neat PHA production capacity metric based on a third-party assessment at December 31, 2024, 50% of the shares vest if capacity is 68 million pounds, 100% vest if capacity is 81 million pounds or higher, with prorated vesting between 68 million pounds and 81 million pounds.
Performance Shares [Member] | Neat PHA Production Capacity Metric [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	$ 202,000						$ 81,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	202,000						81,000
Performance Shares [Member] | Neat PHA Production Capacity Metric [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	177,000						68,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)	$ 177,000						$ 68,000
Performance Shares [Member] | Neat PHA Revenue Metric [Member]
Stock-Based Compensation (Details) [Line Items]
Vesting description							30% of the shares are subject to a total PHA revenue metric based on 2024 financial results. 50% of these shares vest if total PHA revenue is $151 million, 100% vest if total PHA revenue is $189 million or higher, with prorated vesting between $151 million and $189 million.
Performance Shares [Member] | Neat PHA Revenue Metric [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value							$ 189,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)							189,000
Performance Shares [Member] | Neat PHA Revenue Metric [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value							151,000
Share-based Compensation Arrangement fair value of shares vested amount (in Dollars)							$ 151,000
Stock Option
Stock-Based Compensation (Details) [Line Items]
Number of Shares, Granted			0			146,666
Long term liability			$ 500					500
Stock Option | Selling, general and administrative [Member]
Stock-Based Compensation (Details) [Line Items]
Stock-based compensation expense								(400)
Market Based Restricted Shares [Member]
Stock-Based Compensation (Details) [Line Items]
Number of Shares, Granted										1,517,840
Stock-based compensation expense			$ 4,600			$ 4,700		$ 13,900	$ 13,900
Cash Settled Options [Member]
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units								920,641
Issuance of common stock								920,641
Number of Shares, Granted					1,050,000		972,222
2020 ESPP [Member]
Stock-Based Compensation (Details) [Line Items]
Performance stock and performance stock units								182,037
ESPP plan, percentage of stock discount								15%
Share-based compensation, authorized shares			2,571,737					2,571,737
Number of remaining shares			2,306,519					2,306,519
Issuance of common stock								182,037
2020 Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Share-based compensation, remained authorized for Issuance			1,391,425					1,391,425			1,657,240

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of stock based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	$ 14,324	$ 14,305	$ 42,933	$ 42,550
Cost of revenue [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	2	22	6	60
Selling, general and administrative [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	12,493	12,437	37,643	37,010
Research and Development ]Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount	$ 1,829	$ 1,846	$ 5,284	$ 5,480

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity under our equity plans - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				9 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Beginning	11,950,598	12,044,231	11,844,644		11,844,644
Number of Shares, Granted			204,254
Number of Shares, Forfeited	(50,150)	(93,633)	(4,667)
Number of Shares, Exercisable	5,217,843				5,217,843
Number of Shares, Ending	11,900,448	11,950,598	12,044,231		11,900,448	11,844,644
Number of Shares, Vested and expected to vest	11,900,448				11,900,448
Weighted Average Exercise Price, Beginning (in Dollars per share)	$ 14.02	$ 14.04	$ 14.23		$ 14.23
Weighted average grant-date fair value of options granted (in Dollars per share)				$ 1.97
Weighted Average Exercise Price, Granted (in Dollars per share)			2.58
Weighted Average Exercise Price, Ending (in Dollars per share)	14.02	$ 14.02	$ 14.04		14.02	$ 14.23
Weighted Average Exercise Price, Exercisable (in Dollars per share)	5				5
Weighted Average Exercise Price, Vested and expected to vest (in Dollars per share)	$ 14.02				$ 14.02
Weighted Average Remaining Contractual Term (Years)		6 years 2 months 19 days	6 years 5 months 23 days		5 years 11 months 15 days	6 years 8 months 15 days
Weighted Average Remaining Contractual Term (Years), Exercisable	4 years 29 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	5 years 11 months 15 days
Aggregate Intrinsic Value, Beginning (in Dollars)		$ 852,617
Aggregate Intrinsic Value, Ending (in Dollars)			$ 852,617
Aggregate Intrinsic Value, Exercisable (in Dollars)	$ 0				$ 0
Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)	$ 0				$ 0
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Beginning	777,497	624,675	691,448		691,448
Number of Shares, Granted		152,822	6,250
Number of Shares, Vested			(73,023)
Number of Shares, Ending	777,497	777,497	624,675		777,497	691,448
Weighted Average Exercise Price, Beginning (in Dollars per share)	$ 25.41	$ 37.09	$ 28.51		$ 28.51
Weighted average grant-date fair value of options granted (in Dollars per share)			2.62
Weighted average grant-date fair value of options, Other (in Dollars per share)		3.01
Weighted Average Exercise Price, Forfeited (in Dollars per share)			5.86
Weighted Average Exercise Price, Ending (in Dollars per share)	$ 25.41	$ 25.41	$ 37.09		$ 25.41	$ 28.51

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of share based compensation activity (Details) - $ / shares	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options		11,900,448	11,950,598	12,044,231	11,844,644
September 30, 2021 fair value	$ 1.97

Commitments and Contingencies A

Commitments and Contingencies Additional Information (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares
Commitments and Contingencies Disclosure [Abstract]
Royalty per share (in Pounds per share) | $ / shares	$ 0.05
Weight of PHA Sold (in Pounds) | $	$ 500,000,000
Decrease royalty per share (in Pounds per share) | $ / shares	$ 0.025
Loss on forfeiture | $	$ 500